BioShield Develops New Solid Form Antimicrobial - BST 1870 To Be Marketed in the $2 Trillion Worldwide Healthcare Sector
BST 1870 Developed to Become FDA Grade Product
ATLANTA, June 18, 2002. BioShield Technologies, Inc. announced today the development of a new molecular formulation of the trymethoxysilil family in a solid form, high concentrate active ingredient, designed to be used in the healthcare and medical sector.
BioShield Technologies has devoted several years to the development and refining of the new BST 1870. The development of 1870 as a medical-grade solid form antimicrobial/antibacterial has phenomenal potential to be utilized in various medical and healthcare applications and treatments and finally gives BioShield the opportunity to approach the $2 trillion medical industry with this revolutionary new biotechnology. In addition, BST 1870 in solid form also gives BioShield the ability to pursue into markets that do not permit liquid applications, creating entirely new sources of potential revenue and licensee partners
Management stated, "This opens significant potential for BioShield to work with pharmaceutical and biotech companies to take advantage of our core antimicrobial and antibacterial technology. We look forward to unleashing the potential that BST 1870 holds for BioShield and we're extremely excited that we are finally able to approach the healthcare marketplace with a medical- grade product."
The solid form of the BioShield's technology can be added to a wide variety of compounds given the antimicrobial efficacy shown in BioShield other liquid formulations. This new molecule formulation that makes up BST 1870 has no heavy metals, no volatile organic compounds (VOC) and is not regulated by the department of transportation (DOT) as a regulated hazardous material. Research & development of BST 1870 just finished the last toxicological tests showing very low toxicity and no side effects in several different studies conducted by an independent FDA Approved laboratory.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Chemists show it's hip to be square - Their synthetic azetidines could help simplify drug design for neurological diseases
Category:Antiparasitic_agents

Insights into the cellular and molecular changes in male infertility
Category:Medical_researchers
